June 19, 2025
Source: drugdu
42
According to reports from multiple media outlets including 21st Century Business Herald and The Paper, Shan Guohong, global senior vice president of Takeda Pharmaceutical and president of Takeda China, will step down and may join BeiGene next.
8-year veteran
In September 2017, Shan Guohong became the president of Takeda China, which marked the start of Takeda China's business boom. In 2020, Takeda China launched the "Wu Ju Future" five-year development plan, proposing the goal of launching more than 15 innovative products in China by 2025, benefiting more than 10 million Chinese patients.
Under his outstanding leadership, Takeda China has climbed from the 23rd place in the foreign-invested pharmaceutical market to the 9th largest foreign-invested pharmaceutical company, becoming Takeda's third largest market in the world, second only to the United States and Japan, and more than half of its business comes from growth pipelines and newly launched products.
What is even more remarkable is that in the past five years, Takeda has been approved for marketing of 15 innovative products in China, which not only further consolidated its leadership position among multinational biopharmaceutical companies in China, but also made the goals of the 2020 "Wu Ju Future" plan a reality.
However, all good things must come to an end. After Shan Guohong stepped down, Takeda China also quickly made personnel adjustments, appointing Liu Yan, head of the Digestive Disease Business Unit, as acting president of Takeda China Business Unit. She will take over the strategic and operational management of Takeda China Business Unit from July 1, 2025, and her successor to her previous position is also being prepared in full swing.
Regarding Shan Guohong's whereabouts, some media reported that he will join BeiGene, but BeiGene has not responded yet.
Takeda continues to adjust
In recent years, Takeda Pharmaceutical has actively implemented a "slimming plan" and restructuring on a global scale, aiming to optimize the business structure and improve operational efficiency and competitiveness. As one of Takeda's important markets worldwide, China's personnel changes are undoubtedly a continuation and deepening of this global strategy.
Since completing the acquisition of Shire Pharmaceuticals in 2019, Takeda has embarked on a large-scale restructuring journey, promising to sell non-core assets to reduce debt. At the global level, Takeda has sorted out and integrated multiple business segments and regional structures, eliminated some business units with poor performance or poor strategic fit, and streamlined management levels to improve decision-making efficiency.
The Chinese market is full of opportunities and challenges for Takeda. With the rapid development of the Chinese pharmaceutical market and changes in the policy environment, a series of new situations and new problems have emerged. The increasingly stringent medical insurance cost control policies and the expansion of the scope of drug procurement have effectively reduced drug prices and reduced the burden on patients, but have also compressed the profit margins of pharmaceutical companies, posing a huge impact on the traditional operating model.
At the same time, local innovative pharmaceutical companies have sprung up like mushrooms after a spring rain. With their deep understanding of the local market, flexible operating mechanisms and continuous R&D investment, they have made breakthroughs in multiple therapeutic areas and engaged in a head-on confrontation with foreign pharmaceutical companies.
In such a complex market environment, Takeda needs a more flexible, efficient and innovative management structure to respond to market changes.
This personnel change may be a positive adjustment made by Takeda China to adapt to the new situation, so as to accurately seize opportunities in the fierce market competition, promote sustained business growth, and provide solid and stable "China support" for the advancement of the company's global strategy.
https://news.yaozh.com/archive/45645.html
By editoryour submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.